跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

SML2758

Sigma-Aldrich

达格列净丙二醇一水合物

≥98% (HPLC)

别名:

(1S)-1,5-酐-1-C-[4-氯-3-[（4-乙氧基苯基）甲基]苯基]-D-葡萄糖醇（S）-丙烷-1,2-二醇（1:1）一水合物, BMS 512148 丙二醇水合物, BMS-512148 丙二醇水合物, 达格列净丙二醇水合物, 达格列净（S）-丙二醇一水合物, （2S,3R,4R,5S,6R）-2-（3-（4-乙氧基苄基）-4-氯苯基）-6-羟甲基-四氢-2H-吡喃-3,4,5-三醇丙二醇一水合物

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C21H25ClO6·C3H8O2·H2O
CAS号:
960404-48-2
分子量:
502.98
MDL编号:
MFCD28167768
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

100

方案

≥98% (HPLC)

表单

powder

旋光性

[α]/D +17 to +25, c = 1.0 in chloroform-d

储存条件

desiccated

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

−20°C

SMILES字符串

Clc1c(cc(cc1)[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO)Cc2ccc(cc2)OCC.O[C@H](CO)C.O

InChI

1S/C21H25ClO6.C3H8O2.H2O/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21;1-3(5)2-4;/h3-8,10,17-21,23-26H,2,9,11H2,1H3;3-5H,2H2,1H3;1H2/t17-,18-,19+,20-,21+;3-;/m10./s1

InChI key

GOADIQFWSVMMRJ-UPGAGZFNSA-N

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

口服活性，强效和选择性肾钠依赖性葡萄糖共转运蛋白2（SGLT2；SLC5A2）抑制剂，在体内具有降血糖功效。
达格列净（BMS-512148）是一种口服活性、有效和选择性的肾钠依赖性葡萄糖共转运蛋白2（SGLT2；SLC5A2）抑制剂（人/大鼠SGLT2 IC50 = 1.1/3 nM，而人/大鼠SGLT1 IC50 = 1.39/0.6 μM；R-甲基-D-吡喃葡萄糖苷（AMG）摄取测定以及相应的CHO转染子）。达格列净通过防止肾脏葡萄糖重吸收过程并促进尿液中葡萄糖排泄，具有良好的药代动力学特性和口服利用度（口服1 mg/kg和6.6 mg/kg后，在大鼠和狗中分别降低了84%和83%），从而降低了血糖水平（在链脲佐菌素（STZ）诱导的高血糖大鼠中，在口服0.1 mg/kg后5小时降低了55%）体内。

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000379679
0000303378
0000303378
0000379679
0000199642

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

M Obermeier et al.
Drug metabolism and disposition: the biological fate of chemicals, 38(3), 405-414 (2009-12-10)
(2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyl-tetrahydro-2H-pyran-3,4,5-triol (dapagliflozin; BMS-512148) is a potent sodium-glucose cotransporter type II inhibitor in animals and humans and is currently under development for the treatment of type 2 diabetes. The preclinical characterization of dapagliflozin, to allow compound selection and prediction of pharmacological
Dapagliflozin - a breakthrough in the search for drugs to treat HFrEF.
Karina Huynh
Nature reviews. Cardiology, 16(12), 700-700 (2019-10-04)
Wei Meng et al.
Journal of medicinal chemistry, 51(5), 1145-1149 (2008-02-12)
The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME
Hiroki Yoshioka et al.
Obesity research & clinical practice, 13(5), 505-510 (2019-08-31)
Chronopharmacology is the study of the varying responses of drugs to changes in biological timing and endogenous periodicities. The selective sodium-glucose cotransporter 2 inhibitor, dapagliflozin, is a globally prescribed antihyperglycemic drug. Although dapagliflozin is usually administered once a day, the
Nannan Zhang et al.
Cardiovascular diabetology, 18(1), 107-107 (2019-08-21)
Heart failure with preserved ejection fraction (HFpEF) is a difficult disease with high morbidity and mortality rates and lacks an effective treatment. Here, we report the therapeutic effect of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), on hypertension + hyperlipidemia-induced HFpEF in a
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门